InvestorsObserver
Sign Up Login

XTLB Xtl Biopharma ADR

$2.59 $0.00 (0.00%)
15 Minute Delayed Price Enable Real-Time Price
Add to Watchlist Compare
Overall

XTLB Stock Analysis Overview

What this means: InvestorsObserver gives Xtl Biopharma ADR (XTLB) an overall rank of 50, which is below average. Xtl Biopharma ADR is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 50 means that 50% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

XTLB Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

XTLB Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

XTLB Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

XTLB Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

XTLB Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

XTLB Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

XTLB Stock Analysis Overview

What this means: InvestorsObserver gives Xtl Biopharma ADR (XTLB) an overall rank of 50, which is below average. Xtl Biopharma ADR is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 50 means that 50% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full XTLB report

XTLB Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

XTLB Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

XTLB Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

XTLB Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

XTLB Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

XTLB Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Xtl Biopharma ADR (XTLB) Analyst Forecast

XTLB Price, Volume, Earnings, and Dividend Date

  • Last Price $2.59
  • Previous Close $2.59
  • Change $0.00
  • Open $2.51
  • Volume 7,560
  • Avg. Volume (100-day) 473,865
  • Market Cap 14,113,068
  • Days Range 2.49 - 2.63
  • 52-week Range 0.75 - 4.99
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 05/21/24
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 2.510
  • PEG Ratio —

Xtl Biopharma ADR (XTLB) Company Description

XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE). hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.

Xtl Biopharma ADR (XTLB) Stock Chart

View Interactive XTLB chart

My Watchlists

Top Stocks in Biotechnology